Alumis (ALMS) investor relations material

Key achievements and recent progress

• Advanced two TYK2 inhibitor molecules, envudeucitinib and A-005, with a robust pipeline and completed a merger with Acelyrin to strengthen cash position and enable key data readouts.

• Presented top-line phase III psoriasis data for envudeucitinib, showing PASI 90 values averaging 65% and PASI 100 above 40% at 24 weeks, positioning it at the top end of oral therapies.

• Demonstrated rapid onset of action and consistent safety profile across trials, with no need for dose reduction from phase I to III.

• Preparing to share additional quality of life and itch data at AAD, with a late-breaker presentation scheduled.

• Developed a once-daily formulation for envudeucitinib, with ongoing refinement for future lifecycle extension and patent benefits.

Market outlook and competitive positioning

• Expects significant growth in the oral psoriasis market, with patients moving from topicals to orals and staying longer on oral therapies before switching to biologics.

• Anticipates distinct market segments and physician preferences, with multiple oral drugs coexisting and a competitive profile for envudeucitinib.

• Key decision drivers for clinicians include skin clearance (PASI 90/100), itch relief, quality of life, and safety, with itch being a major differentiator for TYK2 inhibitors.

• Long-term 48-week data and NDA filing planned for the second half of the year, including three-year safety data from phase II extension.

• Commercial launch preparations underway, with strategic considerations for internal scaling versus partnerships, especially given the broad TYK2 franchise potential.

Pipeline expansion and future plans

• Lupus phase II-B readout expected, with trial design optimized to reduce placebo effect and enrich for patients with skin involvement.

• Confident in lupus success based on genomics, prior TYK2 data, and interferon pathway targeting; primary endpoint is BICLA for better skin response measurement.

• Evaluating up to 20 indications for TYK2 franchise, prioritizing based on IL-23 and interferon axes, and leveraging two molecules for strategic flexibility.

• A-005, the brain-penetrant TYK2 inhibitor, is advancing toward a phase II MS study, with potential in other neuroinflammatory and neurodegenerative diseases.

• Ongoing biomarker work aims to predict response, with more data expected later in the year or next year.